Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
GLP-1 medications changed everything and Retatrutide may represent the next major leap
Recent systemic review and meta-analysis demonstrated, that treatment with functional agonists of GLP-1 which included both GLP-1RAs and DPP4 inhibitors resulted in a significant reduction of depression rating scores and tended to be superior over control treatments, which supports the hypothesis of their antidepressant action in humans
Several cardiovascular outcome trials (CVOTs) have also reported that GLP-1 RAs may be associated with mitigating kidney-related outcomes, including albuminuria, decline in eGFR and the risk of end-stage kidney disease, independent of their effects on glycemic control 14,15,17,26,27
Compounded medications are not reviewed or approved by the FDA for safety or efficacy
Commonly used GLP-1 RAs include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity)
US$ 29.38
US$ 23.06
US$ 22.53
